Over the past 7 years, multiple agents have been approved for metastatic castrate-resistant prostate cancer, bringing prolonged survival, improved quality of life, and increased complexity of decision-making to patients and clinicians. This case-based activity reviews these treatments as well as the importance of communicating with patients about the potential benefits and risks of each therapy, while providing realistic expectations for improved quality of life and prolonged survival.
eNewsletter with interactive benchmarking
After completing this activity, participants should be better able to:
- Identify patients with prostate cancer who would benefit from first-line combination docetaxel and androgen deprivation therapy according to evidence-based guidelines
- Select the most appropriate regimen for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) based on clinical trial data, providing optimal sequencing of therapy for individual patients
- Develop strategies to recognize and manage adverse events when treating patients with mCRPC
Oncology nurse practitioners, physician assistants, and nurses
There are no prerequisites to participate in this activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.0, which are eligible for 1.0 pharmacology credits
Course director: J. Mark Sloan, MD, Boston University School of Medicine
CNE course advisor: Jennifer Brock, RN, BSN, OCN, Dana Farber Cancer Institute
This program has been reviewed and is approved for a maximum of 1.00 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of July 31, 2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program was cosupported by educational grants from Astellas and Medivation, Inc., a Pfizer Company; Celgene Corporation; Genzyme, a Sanofi Company; Eisai, Inc. and Helsinn; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Takeda Oncology; and TESARO, Inc. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
This activity is supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, and Genzyme, a Sanofi Company.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the American Academy of Physician Assistants, Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Gomella: consultant: AbbVie, Astellas, Bayer, Janssen.
Dr Sloan: consultant: Alexion, Incyte, Molecular Templates, Stemline; grant/research support: Gilead.
The Planning Committee for this activity included Jennifer Brock, RN, BSN, OCN, of Dana Farber Cancer Institute; Patti-Ann Collins, DNP, MSN, MBA, RN (Lead Nurse Planner), of Healthcare Advocacy Services; Mark Christiansen, PhD, PA-C, of University of the Pacific; Jason Worcester, MD, Jody Walker, MS, and Julie L. White, MS, of Boston University School of Medicine; and Ruth Cohen, Devera Pine, Warren Beckman, and Margaret Inman of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the eNewsletter in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: July 31, 2017
Expiration date: July 30, 2018
Internet Explorer 8.0+ for Windows 2000, 2003, XP, Vista, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+
© 2018 Practicing Clinicians Exchange. All Rights Reserved. OPCE89816-7C